# Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

> **NCT02551991** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 56 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** nal-IRI
- **DRUG:** 5 fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02551991
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-19
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551991, "Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02551991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*